Publications by authors named "Cassandre Petit"
What are the therapeutic options for previously treated myelofibrosis?
Expert Rev Hematol
November 2024
Article Synopsis
- The JAK/STAT signaling pathway disruption is key in myelofibrosis (MF), and JAK inhibitors (JAKi) have become crucial for treatment, guiding a shift in how MF is managed.
- This review discusses treatment options for patients who don't respond to first-line JAKi, showcasing alternative JAKi and other strategies based on thorough research from various databases.
- Ruxolitinib's benefits may decline after a few years, leading to complications; newer JAKi provide alternatives, while stem cell transplants can offer a cure for some, highlighting the need for future research on innovative treatments and collaborations among different stakeholders.
Erythroblastic synartesis is a rare cause of acquired dyserythropoiesis. Only 9 cases have been previously reported. We hereby report 3 cases of patients diagnosed with erythroblastic synartesis associated with monoclonal immunoglobulin and an overt malignant lymphoid disorder.
View Article and Find Full Text PDF